Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citigroup Inc. (C) vs TG Therapeutics Inc (TGTX) Price & Performance

Citigroup Inc.Trade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Citigroup Inc. vs TG Therapeutics Inc — how do they compare? Citigroup Inc. trades at $137.77 (market cap $227.75B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Citigroup Inc. is far larger — about 29.8× TG Therapeutics Inc's market cap, and Citigroup Inc. pays a 1.97% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.

CTGTX
Market Cap
$227.75B$7.64B
Sector
FinancialsHealth
52-Week High
$145.67$59.06
52-Week Low
$92.59$26.94
Dividend Yield
1.97%
Enterprise Value
$7.84B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citigroup Inc.

Citigroup (C) trades at $137.93, up 2.0% with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with Q2 2026 EPS beating estimates at $3.06 versus $2.65 expected, revenue growth trending upward from $85.21B in 2025 to $91.4B projected for 2026, and improving net income margins. Recent corporate developments include strategic hires and dividend declarations, while institutional sentiment remains positive with 59% buy ratings.

The outlook for C remains favorable with a consensus price target of $154.38 offering 12% upside potential. Key opportunities include continued earnings growth and efficiency gains from the transformation plan. Risks include volatile cash flows from operations and elevated debt levels, though the current valuation at P/E 14.63 appears reasonable relative to historical performance.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citigroup Inc.

Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.

Read more on C

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX